NCT03381170View on ClinicalTrials.gov

An Extension of the TG1101-RMS201 Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
BIOLOGICAL

Ublituximab

Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E

Trial Locations (8)

37922

TG Therapeutics Investigational Trial Site, Knoxville

40513

TG Therapeutics Investigational Trial Site, Lexington

43081

TG Therapeutics Investigational Trial Site, Westerville

43210

TG Therapeutics Investigational Trial Site, Columbus

78258

TG Therapeutics Investigational Trial Site, San Antonio

78681

TG Therapeutics Investigational Trial Site, Round Rock

80045

TG Therapeutics Investigational Trial Site, Aurora

91105

TG Therapeutics Investigational Trial Site, Pasadena

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT03381170 - An Extension of the TG1101-RMS201 Trial | Biotech Hunter | Biotech Hunter